Neuroprotection in experimental stroke with targeted neurotrophins.
More than 30 neurotrophins have been identified, and many of them have neuroprotective effects in brain ischemia or injury. However, all the clinical trials with several neurotrophins for the treatment of acute ischemic stroke or neurodegenerative diseases have failed so far, primarily because of their poor blood-brain barrier (BBB) permeability. This article is an overview of recent progress in the research focused on BBB targeted neurotrophins using a chimeric peptide approach, in which antitransferrin receptor antibody was used as a BBB delivery vector, and neurotrophin peptide was conjugated to the antibody via the avidin/biotin technology. Vasoactive intestinal peptide was the first model chimeric peptide to show an enhanced CNS effect after noninvasive peripheral administration. Brain-derived neurotrophic factor (BDNF) chimeric peptide was neuroprotective in rats subjected to transient forebrain ischemia, permanent focal ischemia, or transient focal ischemia. Delayed treatments with the BDNF chimeric peptide showed an effective time window of 1-2 h after ischemia. Basic FGF chimeric peptide was highly effective in the reduction of infarct volume in the rat model of permanent focal ischemia, with lowest effective dose of 1 mug per rat. Future studies in this exciting area include genetically engineered fusion proteins or humanized antibodies for BBB drug targeting with less immunogenicity and reduced working burden in the chemical conjugation, the use of antihuman insulin receptor antibody for higher BBB delivery efficiency, and combination therapies using chimeric neurotrophins plus other neuroprotectants to achieve additive or synergistic effects.
Wu
Dafang
D
Department of Radiology, Wayne State University School of Medicine, Children's Hospital of Michigan, PET Center, Detroit, Michigan 48201, USA. dwu@pet.wayne.edu
D000818:Animals; D001812:Blood-Brain Barrier; D002545:Brain Ischemia / Q000188:drug therapy; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011990:Receptors, Transferrin / Q000187:drug effects; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology
D019208:Brain-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D011990:Receptors, Transferrin; D011993:Recombinant Fusion Proteins; D016222:Fibroblast Growth Factor 2; D014660:Vasoactive Intestinal Peptide
Neurology. 1999;53(7 Suppl 4):S3-14
10532643
Am J Cardiovasc Drugs. 2002;2(5):303-13
14727960
Pharm Res. 2000 Jan;17(1):63-9
10714610
Pharm Res. 2000 Mar;17(3):266-74
10801214
Stroke. 2000 Sep;31(9):2212-7
10978054
Brain Res. 2001 Jan 19;889(1-2):49-56
11166685
Stroke. 2001 Jun;32(6):1378-84
11387502
J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2 Suppl 1):S46-56; quiz S56-7
15095935
Physiol Rev. 1968 Jul;48(3):534-69
4875350
Science. 1970 Sep 18;169(3951):1217-8
5450698
Am J Physiol. 1980 Apr;238(4):H449-56
7377315
Nature. 1984 Nov 8-14;312(5990):162-3
6095085
Brain Res. 1984 Nov 19;322(1):9-16
6549149
Behav Brain Res. 1985 Sep;17(1):17-24
4041219
J Neurosci. 1986 Aug;6(8):2155-62
3746405
Proc Natl Acad Sci U S A. 1986 Dec;83(23):9231-5
3466184
J Cereb Blood Flow Metab. 1987 Jun;7(3):315-26
3108270
Nature. 1988 Oct 13;335(6191):639-42
2845276
J Neurol Sci. 1989 Jul;91(3):311-21
2671268
J Neurosci. 1991 Sep;11(9):2914-9
1880556
Science. 1991 Nov 22;254(5035):1208-10
1957172
J Neural Transm Park Dis Dement Sect. 1992;4(1):79-95
1540306
Nature. 1992 Dec 24-31;360(6406):753-5
1281520
Adv Cancer Res. 1993;60:1-41
8417497
J Neurosurg. 1993 Feb;78(2):257-66
8421208
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2618-22
8385339
Nature. 1993 May 20;363(6426):266-70
8487864
J Cereb Blood Flow Metab. 1994 Jan;14(1):70-4
8263060
J Pharmacol Exp Ther. 1994 Apr;269(1):344-50
8169841
Neurosurgery. 1994 Feb;34(2):323-31; discussion 331
8177394
Pharm Res. 1994 May;11(5):738-46
8058646
Science. 1994 Aug 19;265(5175):1107-10
8066451
J Pharmacol Exp Ther. 1995 Apr;273(1):161-7
7714762
N Engl J Med. 1995 Dec 14;333(24):1581-7
7477192
J Drug Target. 1995;3(2):159-65
7496729
J Clin Invest. 1996 May 15;97(10):2299-307
8636410
J Pharmacol Exp Ther. 1996 Oct;279(1):77-83
8858978
Annu Rev Pharmacol Toxicol. 1997;37:239-67
9131253
J Immunol. 1997 May 15;158(10):4797-804
9144494
J Clin Invest. 1997 Oct 1;100(7):1804-12
9312181
Pharm Res. 1998 Apr;15(4):576-82
9587954
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):254-9
9874805
Stroke. 1999 Feb;30(2):427-31; discussion 431-2
9933283
Cerebrovasc Dis. 1999 May-Jun;9(3):131-5
10207203
Neurology. 1999 Apr 22;52(7):1427-33
10227630
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Jun;1(3):201-6
11464953
J Pharmacol Exp Ther. 2002 May;301(2):605-10
11961063
J Drug Target. 2002 May;10(3):239-45
12075825
Am J Med Sci. 2002 Jul;324(1):14-30
12120821
Am J Health Syst Pharm. 2002 Sep 15;59(18):1723-35
12298110
Cerebrovasc Dis. 2002;14(3-4):239-51
12403958
Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20
12507405
Adv Exp Med Biol. 2002;513:397-430
12575830
Neuroscience. 2003;118(1):107-13
12676142
J Neurosci Nurs. 2003 Apr;35(2):114-8
12795039
Br J Clin Pharmacol. 2004 Jan;57(1):15-26
14678336
Cerebrovasc Dis. 2004;17 Suppl 1:153-66
14694293
Stroke. 2004 Jan;35(1):205-11
14671248
Int J Neurosci. 2004 Feb;114(2):183-96
14702207
JAMA. 1999 Dec 1;282(21):2003-11
10591382